Severin Jacobi

1. High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy
   2018/11/09 by Felicitas Rataj, Severin J. Jacobi, Severin Jacobi +11 · 25 citations
   Medicine · Immunology and Microbiology · #CAR-T cell therapy research #Monoclonal and Polyclonal Antibodies Research #Immunotherapy and Immune Responses